Continuous-Infusion Cyclophosphamide in Combination with Teniposide and Dexamethasone in Refractory Myeloma

References

• Alberts D. S., Balcerzak S. P., Bonnet J. D., Stephens R. L. Phase II trial of mitoxantrone in multiple myeloma a southwest oncology group study. Cancer Treat. Rep. 1985; 69: 1321–1323
   PubMedGoogle Scholar
• Buzaid A. C., Durie B. G. M. Management of refractory myeloma: a review. J. of Clin. Oncol. 1988; 6: 889–905
   PubMed Web of Science ®Google Scholar
• Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal Medicine 1984; 310: 1353–1356
   PubMed Web of Science ®Google Scholar
• Alexanian R., Barlogie B., Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann. Intern. Med 1986; 105: 8–11
   PubMed Web of Science ®Google Scholar
• Collin R., Greaves M., Preston F. E. Potential value of vincristine-adriamycin-dexamethasone combination chemotherapy (VAD) in refractory and rapidly progressive myxoma. Eur. J. Haemal. 1987; 39: 203–208
   PubMed Web of Science ®Google Scholar
• Forgeson G. V., Selby P., Lakhani S., Zulian G., Viner C., Maitland J., McElwain T. J. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br. J. Cancer 1988; 58: 469–473
   PubMed Web of Science ®Google Scholar
• Friedemberg W. R., Kyle R. A., Knospe W. H., Bennett J. M., Tsiatis A. A., Oken M. M. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am. J. Haematol. 1991; 36: 171–175
   PubMed Web of Science ®Google Scholar
• Alexanian R., Barlogie B., Ventura G. Chemotherapy for resistant and relapsing multiple myeloma. European Journal Haemalology 1989; 43(Suppl 51)140–144
   Google Scholar
• Kaye S. B., Kerr D. J. Multidrug resistance: clinical relevance in haematological malignancies. Blood Rev. 1991; 5: 38–41
   PubMed Web of Science ®Google Scholar
• Dalton W. S., Grogan T. M., Meltzer P. S., Scheper R. J., Durie B. G. M., Taylor C. W., Miller T. P., Salmon S. E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol 1989; 7: 415–424
   PubMed Web of Science ®Google Scholar
• Salmon S. E., Dalton W. S., Grogan T. M., Plezia P., Lehnert M., Roe D. J., Miller T. P. Multidrug-resistant drug myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44–50
   PubMed Web of Science ®Google Scholar
• Lenhard R. E., Oken M. M., Barnes J. M., Humphrey R. L., Glick J. H., Silverstein W. N. High dose cyclophosmamide, an effective treatment for advanced refractory multiple myeloma. Cancer 1984; 53: 1456–1459
   PubMed Web of Science ®Google Scholar
• Brock N. The oxazaphosphorines. Cancer Treatment Review 1983; 10: 17–24
   PubMed Web of Science ®Google Scholar
• Guthrie T. High-dose, continuous-infusion cyclophosphamide, cytarabine, vincristine, and prednisone for remission induction in refractory adult acute leukemia. Cancer 1987; 59: 1255–1257
   PubMed Web of Science ®Google Scholar
• Tirelli U., Carbone A., Zagonel V., Brema F., Veronesi A., Grigoletto E., Volpe R. Phase II study of teniposide (VM-26) in multiple myeloma. American Journal Clinical Oncology 1985; 8: 329–331
   PubMed Web of Science ®Google Scholar
• McLntire O. R., Pajak T. F., Kyle R. A., Cornwell G. G., Leone L. Response rate and survival in myeloma patients receiving prednisone alone. Medical Pediatric Oncology 1985; 13: 239–243
   PubMedGoogle Scholar
• Dombernowsky P., Nissen N. I. Combination chemotherapy with 4′demethyl-epipodophyllotoxin VP-16–213 in L-1210 leukemia. European Journal Cancer Clinical Oncology 1976; 12: 181–188
   Google Scholar
• Chang T. T., Gulati S. C., Chou T. C., Vega R., Gandola L., Ezzat Ibrahim S. M., Yopp J., Colvin M., Clarkson B. D. Synergistic effect of 4-Hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. Cancer Research 1985; 45: 2434–2439
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Non parametric estimation from incomplete observations. Journal American Statistical Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Lokhorst H. M., Meuwissen O., Bast E., Dekker A. W. VAD chemotherapy for refractory multiple myeloma. Br. J. Haemal. 1989; 71: 25–30
   PubMed Web of Science ®Google Scholar
• Case D. C., Lee B. J., Clarkson B. D. Improved survival times in multiple myeloma treated with Melphalan, Prednisone, Cyclophosphamide, Vincristine and BCNU: M-2 protocol. American Journal Medicine 1977; 63: 897–903
   PubMed Web of Science ®Google Scholar
• Cavo M., Galieni P., Tassi C., Gobbi M., Tura S. M-2 protocol for melphalan-resistant and relapsing multiple myeloma. European Journal Haemalology 1988; 40: 168–173
   PubMed Web of Science ®Google Scholar
• Galieni P., Cavo M., Grimaldi M., Bonelli M. A., Tassi C., Bontadini A., Dinota A., Gobbi M., Lauria F., Tura S. Intermediate-dose intravenous melphalan therapy of multiple myeloma. Proceedings International Conference on Multiple Myeloma, Bologna, 1989, 251
   Google Scholar
• Gimsing P., Bjerrum O., Brandt E., Ellegaard J., Evensen S., Hansen M., Hedenus M., Hippe E., Keldesen N., Palva I., Rodjer S., Talstad I., Westin J., Winsloff F. for the Nordic Myeloma Study Group Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. Br. J. Haemal. 1991; 77: 73–79
   PubMed Web of Science ®Google Scholar
• Reiffers J., Marit G., Boiron J. M., Bernard P., Vezon G., Broustet A. Collection of peripheral blood stem cells and their use for autologous transplantation in patients with high-risk myeloma. Proceedings International Conference on Multiple Myeloma, Bologna, 1989, 273
   Google Scholar
• Barlogie B., Velasquez W., Alexanian R., Cabanillas F. Etoposide, dexamethasone, cytarabine and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. Journal Clinical Oncology 1989; 7: 1514–1517
   PubMed Web of Science ®Google Scholar
• Alexanian R., Dimopoulos M., Barlogie B., Vadhan-Raj Champlin R. (1991) Chemotherapy for resistant and relapsing multiple myeloma. Proceedings on Multiple Myeloma from Biology to Therapy, Abstracts book of III International Workshop, Torino, 1991, 105
   Google Scholar
• Bruce W. B., Meeker B. E., Valeriote F. A. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. Journal National Cancer Institute 1966; 36: 233–238
   PubMedGoogle Scholar
• Klein H. O., Wickramanayake D. P., Christian E., Coerper C. Therapeutic effects of single-push or fractionated injections of cyclophosphamide or ifosfamide combined with mesna. Cancer Treatment Reviews 1983; 10: 83–101
   PubMed Web of Science ®Google Scholar
• Tchekmedyian S., Egorin M., Cohen B., Kaplan R., Poplin E., Aisner J. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion. Cancer Chemotherapy Pharmacology 1986; 18: 33–38
   PubMed Web of Science ®Google Scholar
• Solidoro A., Otero J., Vallejos C., Casanova L., Salas F., Pasco T., Quiroz L., Orlandini O., Marciai J. Intermittent continuous iv infusion of high-dose cyclophosphamide for remission induction in acute lymphocytic leukemia. Cancer Treatment Reports 1981; 65: 213–218
   PubMedGoogle Scholar
• Ciolli S., Leoni F., Caporale R., Salti F., Rossi Ferrini P. Continuous-infusion cyclophosphamide plus vincristine, cytosine-arabinoside and prednisone for refractory acute lymphoblastic leukemia in adults. Haematologica 1991; 76: 293–297
   PubMedGoogle Scholar
• Mandelli F., Avvisati G., Amadori S., Boccadoro M., Gernone A., Lauta V., Marmont F., Petrucci M., Tribalto M., Vegna M. L., Dammacco F., Pileri A. Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New Engl. J. Med. 1990; 322: 1430–1434
   PubMed Web of Science ®Google Scholar
• Alexanian R., Yap B. S., Bodey G. Prednisone pulse therapy for refractory myeloma. Blood 1983; 62: 572–577
   PubMed Web of Science ®Google Scholar
• Leoni F., Ciolli S., Salti F., Teodori, Rossi P., Ferrini P. Teniposide, dexamethasone and continuous-infusion cyclophosphamide in advanced refractory myeloma. Br. J. Haemat. 1991; 77: 180–184
   PubMed Web of Science ®Google Scholar